التفاصيل البيبلوغرافية
| العنوان: |
Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS. |
| المؤلفون: |
Nicol, Edith1 (AUTHOR), Do, Bernard2,3 (AUTHOR), Vignes, Marina3 (AUTHOR), Annereau, Maxime2,3 (AUTHOR), Paul, Muriel4,5 (AUTHOR), Wolkenstein, Pierre6,7 (AUTHOR), Touboul, David1 (AUTHOR), Secretan, Philippe-Henri8 (AUTHOR) philippe-henri.secretan@universite-paris-saclay.fr |
| المصدر: |
Pharmaceutical Development & Technology. Oct2024, Vol. 29 Issue 8, p855-861. 7p. |
| مصطلحات موضوعية: |
LIQUID chromatography-mass spectrometry, TOPICAL drug administration, MASS spectrometry, NEUROFIBROMATOSIS 1, DESORPTION |
| مستخلص: |
Understanding drug behavior within the skin, especially for photosensitive compounds, is crucial for developing effective and safe topical therapies. This study employs Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI-MSI) and Liquid Chromatography-Mass Spectrometry (LC-MS/MS) to investigate the skin permeation and photostability of selumetinib, a MEK inhibitor used in treating type 1 neurofibromatosis (NF1). The highest amounts of selumetinib in the skin sections were obtained when using the gel formulation, suggesting that it is to be preferred to cream formulations to achieve higher permeation of the drug. Our study also revealed that selumetinib is amenable to photodegradation in ex vivo skin explants, and yields one main degradation product, whose degradation is likely triggered by hydrogen abstraction. MALDI-MSI results showed selumetinib and its degradation product concentrate in skin appendages, indicating these structures might serve as drug reservoirs, potentially prolonging retention and efficacy. This study demonstrates that combining MALDI-MSI with LC/MS-MS can highly contribute to the characterization of the fate of photosensitive compounds in the skin, an essential prerequisite to the development of compound-specific photoprotective measures. It will also pave the way for innovative topical delivery strategies for NF1 treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pharmaceutical Development & Technology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |